Daiwa: Raises target price for SUNNY OPTICAL (02382) to HKD 73, reiterates "Outperform" rating.
Upgraded profit forecasts to reflect revenue growth and cost control effectiveness in the first half of the year; the banks earnings per share forecast for Sunny Optical is 2% to 6% higher than the market for 2026 to 2027.
Daiwa has released a research report stating that it has raised the target price for Sunny Optical (02382) from HKD 72 to HKD 73, reaffirming its Outperform rating; it has also increased its earnings forecast for 2026 to 2027 by 21% to 27%. The firm indicated that the upgrade in earnings forecast reflects the revenue growth and the effectiveness of cost control in the first half of the year; its earnings per share forecast for Sunny Optical in 2026 to 2027 is 2% to 6% higher than the market, mainly due to a more optimistic outlook on revenue growth. The firm noted that Sunny Optical's revenue grew by 11% in the first half of the year, driven by the automotive, XR, and IoT businesses, benefiting from robust growth in overseas major client business, with management expecting full-year revenue to remain flat year-on-year. Regarding the XR business, management anticipates that revenue growth will accelerate in 2027.
Related Articles

ABBISKO-B (02256) announced that its novel selective CDK4 inhibitor ABSK192 monotherapy and combination therapy preclinical research results were presented at the 2026 ENA Conference

HUTCHMED (00013): Announces Preclinical Data for HMPL-A830 at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

JOYY, Inc. Sponsored ADR Class A (JOYY.US) Q3 revenue increased 15.6% year-over-year, with all three core businesses growing
ABBISKO-B (02256) announced that its novel selective CDK4 inhibitor ABSK192 monotherapy and combination therapy preclinical research results were presented at the 2026 ENA Conference

HUTCHMED (00013): Announces Preclinical Data for HMPL-A830 at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

JOYY, Inc. Sponsored ADR Class A (JOYY.US) Q3 revenue increased 15.6% year-over-year, with all three core businesses growing






